The iLCT committee, comprising leading Parkinson’s preclinical and clinical specialists, meets annually to evaluate and prioritise detailed drug and compound dossiers that have been written and compiled by Cure Parkinson’s.
Now in its 10th year, the iLCT Committee has evaluated more than 250 drug dossiers, and prioritised over 45 drugs to move forward into clinical trials. Currently, over 3,000 people with Parkinson’s have been involved in the 45 iLCT evaluated therapies. A recent report published by Journal of Parkinson’s Disease showed that nearly 40% of all disease-modifying clinical trials currently taking place have been previously assessed by the International Linked Clinical Trials initiative.
We are sorry that this content was not useful for you
Let us improve this content
Can you tell us how we can improve this content?